| |
 |
This is the category page. Below are all of the research programs that are associated with it
- Multiple Myeloma -
SWOG S0777: A RANDOMIZED PHASE III TRIAL OF CC-5013 (LENALIDOMIDE, NSC-703813) AND LOW DOSE DEXAMETHASONE (LLD) VERSUS BORTEZOMIB (PS-341, nsc-681239), LENALIDOMIDE AND LOW DOSE DEXAMETHASONE (BLLD) FOR INDUCTION, IN PATIENTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA WITHOUT AN INTENT FOR IMMEDIATE AUTOLOGOUS STEM CELL TRANSPLANT
(2_20081105_118)
This study is a Phase III study for patients with previously untreated multiple myeloma. Participants will be randomized to one of two arms. Arm A is the active group and will receive oral dexamethasone once daily on days 1, 8, 15, and 22 and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 6 courses if no disease progression or unacceptable toxicity. Arm B is the experimental arm and participants will receive oral dexamethasone once daily on days 1, 2, 4, 5, 8, 9 and 12; oral lenalidomide once daily on days 1-14 and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for 6 courses if no disease progression or unacceptable toxicity. Participants who intend to undergo stem cell transplant at relapse on either arm will need to undergo peripheral blood stem cell collection after the second course. After completion of the 6 months of induction therapy, participants will receive maintenance therapy comprising of oral dexamethasone one daily on days 1, 8, 15 and 22 and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days until disease progression or unacceptable toxicity. Upon completion of the study, all participants must be followed until death or for six years after initial registration. Participants may be required to have an MRI.
- Multiple Myeloma to Bone:
CALGB: C70604: A RANDOMIZED, PHASE III STUDY OF STANDARD DOSING VERSUS LONGER DOSING INTERVAL OF ZOLEDRONIC ACID IN METASTATIC CANCER
(2_20090604_118)
This is a study for patients with metastatic breast, prostate or multiple myeloma to bone. There are 2 arms to this study; Arm 1 is considered standard treatment and participants will receive Zoledronic acid IV over 15 minutes. This course will repeat every 4 weeks for up to 2 years or until disease progression or unacceptable side effects. Arm 2 is the considered the experimental treatment; participants will receive Zoledronic acid IV over 15 minutes; course repeats every 12 weeks for up to 2 years if no disease progression or unacceptable side effects. Participants will be instructed to take calcium and Vitamin D daily.
|
|
